These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8993603)

  • 61. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid.
    Marsman DS; Goldsworthy TL; Popp JA
    Carcinogenesis; 1992 Jun; 13(6):1011-7. PubMed ID: 1600604
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of clofibric acid and tiadenol on cytosolic long-chain acyl-CoA hydrolase and peroxisomal beta-oxidation in liver and extrahepatic tissues of rats.
    Katoh H; Kawashima Y; Watanuki H; Kozuka H; Isono H
    Biochim Biophys Acta; 1987 Jul; 920(2):171-9. PubMed ID: 2886154
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883.
    Eacho PI; Lanier TL; Brodhecker CA
    Carcinogenesis; 1991 Sep; 12(9):1557-61. PubMed ID: 1893515
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Peroxisome proliferators: species differences in response of primary hepatocyte cultures.
    Elcombe CR; Bell DR; Elias E; Hasmall SC; Plant NJ
    Ann N Y Acad Sci; 1996 Dec; 804():628-35. PubMed ID: 8993577
    [No Abstract]   [Full Text] [Related]  

  • 66. The effect of retinoids and clofibric acid on the peroxisomal oxidation of palmitic acid and of 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoic acid in rat and rabbit hepatocytes.
    Farrants AK; Nilsson A; Trøen G; Blomhoff R; Pedersen JI
    Biochim Biophys Acta; 1993 May; 1168(1):100-7. PubMed ID: 8504135
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
    Cattley RC; DeLuca J; Elcombe C; Fenner-Crisp P; Lake BG; Marsman DS; Pastoor TA; Popp JA; Robinson DE; Schwetz B; Tugwood J; Wahli W
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):47-60. PubMed ID: 9629596
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins.
    Bartles JR; Khuon S; Lin XH; Zhang LQ; Reddy JK; Rao MS; Isoye ST; Nehme CL; Fayos BE
    Cancer Res; 1990 Feb; 50(3):669-76. PubMed ID: 2404574
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds.
    Lalwani ND; Fahl WE; Reddy JK
    Biochem Biophys Res Commun; 1983 Oct; 116(2):388-93. PubMed ID: 6651818
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Growth regulation by peroxisome proliferators: opposing activities in early and late G1.
    Ledwith BJ; Johnson TE; Wagner LK; Pauley CJ; Manam S; Galloway SM; Nichols WW
    Cancer Res; 1996 Jul; 56(14):3257-64. PubMed ID: 8764118
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential expression and ciprofibrate induction of hepatic UDP-glucuronyltransferases for thyroxine and triiodothyronine in Fischer rats.
    Visser TJ; Kaptein E; Harpur ES
    Biochem Pharmacol; 1991 Jul; 42(2):444-6. PubMed ID: 1907145
    [No Abstract]   [Full Text] [Related]  

  • 72. Toxicity of peroxisome proliferators.
    Bieri F; Lhuguenot JC
    Biochimie; 1993; 75(3-4):263-8. PubMed ID: 8507689
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction of hepatocytes in the pancreas of copper-depleted rats following copper repletion.
    Rao MS; Subbarao V; Reddy JK
    Cell Differ; 1986 Mar; 18(2):109-17. PubMed ID: 3513967
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thyroid hormone-independent regulation of mitochondrial glycerol-3-phosphate dehydrogenase by the peroxisome proliferator clofibric acid.
    Shoemaker RL; Yamazaki RK
    Biochem Pharmacol; 1991 Feb; 41(4):652-5. PubMed ID: 1997013
    [No Abstract]   [Full Text] [Related]  

  • 75. Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo.
    de la Iglesia F; McGuire EJ; Haskins JR; Lalwani ND
    Ann N Y Acad Sci; 1996 Dec; 804():310-27. PubMed ID: 8993553
    [No Abstract]   [Full Text] [Related]  

  • 76. Tolerability of fibric acids. Comparative data and biochemical bases.
    Sirtori CR; Calabresi L; Werba JP; Franceschini G
    Pharmacol Res; 1992; 26(3):243-60. PubMed ID: 1437989
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fibrates and C-reactive protein.
    Kostoula A; Elisaf M
    Clin Chim Acta; 2003 Feb; 328(1-2):197. PubMed ID: 12559619
    [No Abstract]   [Full Text] [Related]  

  • 78. [Myositis, hypothyroidism and fibrates].
    Wechsler B; Doumith R; Weil M
    Rev Med Interne; 1991; 12(6):475. PubMed ID: 1792441
    [No Abstract]   [Full Text] [Related]  

  • 79. Cultured hepatocytes for studies of peroxisome proliferation: methods and applications.
    Foxworthy PS; Eacho PI
    J Pharmacol Toxicol Methods; 1994 Feb; 31(1):21-30. PubMed ID: 8186441
    [No Abstract]   [Full Text] [Related]  

  • 80. Carcinogenicity of peroxisome proliferators: evaluation and mechanisms.
    Reddy JK
    Biochem Soc Trans; 1990 Feb; 18(1):92-4. PubMed ID: 2185101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.